Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study
Publication in refereed journal

香港中文大學研究人員
替代計量分析
.

其它資訊
摘要Aim: To investigate whether the benefit of combining aflibercept with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) chemotherapy could be confirmed in patients from the Asia-Pacific region (ClinicalTrials.gov: NCT01661270). Patients & methods: Asian patients with oxaliplatin-pretreated metastatic colorectal cancer were randomized to receive aflibercept or placebo, followed by FOLFIRI. The primary end point was progression-free survival. Results: The intention-to-treat population comprised 332 patients. A clinical supply misallocation resulted in 198/332 (60%) patients receiving at least one cycle of misallocated treatment. Nevertheless, the addition of aflibercept to FOLFIRI was shown to improve progression-free survival (hazard ratio: 0.629; 95% CI: 0.488–0.812). Adverse events were in line with expectations. Conclusion: The beneficial treatment effect associated with the addition of aflibercept to FOLFIRI was confirmed in Asian patients with pretreated metastatic colorectal cancer.

Lay Abstract
The Phase III VELOUR study showed that the addition of aflibercept to FOLFIRI chemotherapy significantly improved outcome in a predominantly western population of patients with metastatic colorectal cancer (mCRC), who had failed prior oxaliplatin-containing therapy. This Phase III study confirmed the aflibercept treatment effect and benefit in patients from the Asia-Pacific region with oxaliplatin-pretreated mCRC.
出版社接受日期27.03.2018
著者Li J, Xu RH, Qin SK, Liu TS, Pan HM, Xu JM, Bi F, Lim R, Zhang SZ, Ba Y, Bai YX, Fan NF, Tsuji A, Yeh KH, Ma B, Wei V, Shi DM, Magherini E, Shen L, Shen L
期刊名稱Future Oncology
詳細描述Epub 2018 Aug 17
出版年份2018
月份8
卷號14
期次20
出版社Future Medicine
頁次2031 - 2044
國際標準期刊號1479-6694
語言英式英語
關鍵詞aflibercept, Asia-Pacific, FOLFIRI, mCRC, oxaliplatin-pretreated
Web of Science 學科類別Oncology;Oncology

上次更新時間 2021-20-01 於 02:26